Riverain Technologies has received regulatory approval for the next-generation version of its imaging software that suppresses bones to help radiologists detect cancerous lung nodules. Advertisement The new version of the software offers greater sensitivity, meaning it can better detect nodules, and better specificity, meaning it yields fewer false positives, said Steve Worrell, Riverains chief technology officer. A recent study of the new version of OnGuard by researchers at University of Chicago Medical Center found that the software identified 25 percent more lung cancers than radiologists found when reviewing the same X-rays without OnGuard. Brandon Glenn MedCity News Brandon Glenn is the Ohio bureau chief for MedCity News.
Categorization (need >= 0.5 to match):